Nanoparticles for the Treatment of Bone Metastasis in Breast Cancer: Recent Advances and Challenges
Xianzhe Yu,Lingling Zhu
DOI: https://doi.org/10.2147/ijn.s442768
IF: 7.033
2024-02-23
International Journal of Nanomedicine
Abstract:Xianzhe Yu, 1, 2 Lingling Zhu 1 1 Department of Medical Oncology, Cancer Center & Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People's Republic of China; 2 Department of Gastrointestinal Surgery, Chengdu Second People's Hospital, Chengdu, Sichuan Province, People's Republic of China Correspondence: Lingling Zhu, Department of Medical Oncology, Cancer Center & Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Wuhou District, Chengdu, Sichuan Province, 610041, People's Republic of China, Tel +86 18782934368, Email Although the frequency of bone metastases from breast cancer has increased, effective treatment is lacking, prompting the development of nanomedicine, which involves the use of nanotechnology for disease diagnosis and treatment. Nanocarrier drug delivery systems offer several advantages over traditional drug delivery methods, such as higher reliability and biological activity, improved penetration and retention, and precise targeting and delivery. Various nanoparticles that can selectively target tumor cells without causing harm to healthy cells or organs have been synthesized. Recent advances in nanotechnology have enabled the diagnosis and prevention of metastatic diseases as well as the ability to deliver complex molecular "cargo" particles to metastatic regions. Nanoparticles can modulate systemic biodistribution and enable the targeted accumulation of therapeutic agents. Several delivery strategies are used to treat bone metastases, including untargeted delivery, bone-targeted delivery, and cancer cell-targeted delivery. Combining targeted agents with nanoparticles enhances the selective delivery of payloads to breast cancer bone metastatic lesions, providing multiple delivery advantages for treatment. In this review, we describe recent advances in nanoparticle development for treating breast cancer bone metastases. Keywords: breast cancer, bone metastasis, nanoparticle, drug delivery Breast cancer (BC) is the primary cause of cancer-associated morbidity, disability, and mortality in women globally. According to the World Health Organization, 2.3 million women worldwide were clinically diagnosed with BC in 2020, among which 685,000 women died from the disease. 1 Metastasis to vital organs remains the leading cause of death in patients with BC. 2 The evolution of solid tumor metastasis is a complex process involving cell invasion from the primary tumor, circulatory system infiltration and extravasation, and distant growth. 3 As the tumor progresses, a locally supportive and receptive microenvironment known as the pre-metastatic niche prepares the tumor cells to colonize before these cells reach distant organs, thus facilitating tumor settlement and metastasis. 4 Some cells that escape from the primary tumor successfully colonize distant organs, whereas most circulating tumor cells are recognized and eliminated by the immune system. Once circulating tumor cells colonize the bone microenvironment, they are referred to as disseminated tumor cells. 5 Different BC subtypes have specific organ preferences for metastasis, with estrogen receptor-positive (ER+) BC showing a propensity for bone metastasis and triple-negative BC typically spreading aggressively to internal organs. 6 Because of its rich vascular supply and the chemo-attractiveness provided by stromal cells, osteoblasts, and osteoclasts that produce large amounts of growth factors and prostaglandins, the bone microenvironment is suitable for tumor cell attachment and proliferation. After reaching the skeleton, disseminated tumor cells settle into a suitable environment or ecological niche. 7,8 This may be partly because bone sinuses have a discontinuous endothelium that facilitates the passage of hematopoietic and other cells, as well as interactions between the tumor and vascular system, leading to a metastatic preference for bone tissue. Various factors increase the likelihood that breast cancer cells will metastasize to the skeleton. 9 Relatively slow blood flow through the bone marrow and the presence of adhesion receptors on endothelial cells in the bone marrow capillaries support the localization of cancer cells in the bone. These features, together with a bone marrow environment rich in growth factors and cytokines, promote the progression of bone metastasis. 10 (Figure 1) Bone metastases affect 80% of patients with advanced BC, causing several bone-related complications such as nerve compression, pathologic fracture, and hypocalcemia. 11 Bone metastases markedly reduce overall survival and lead to poor quality of life for patients because of pain, fa -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology